Hematologic and biochemical characteristics in patients with and without type 2 diabetes mellitus undergoing hemodialysis during a one-year follow-up period
DOI:
https://doi.org/10.24265/horizmed.2018.v18n3.02Keywords:
Type 2 diabetes mellitus, Metabolism, Hemodialysis, Blood, ImmunologyAbstract
Objective: To report if there are hematologic and biochemical differences among patients with and without type 2 diabetes mellitus (T2DM) undergoing hemodialysis (HD). Materials and methods: An observational, retrospective, cohort study of patients treated in the Renal Health Program at the Centro de Prevención de Enfermedad Renal S.A.C. (CENPER) in Lima, Peru. The hematologic and biochemical parameters of 3 patients with T2DM and 3 patients without T2DM undergoing HD were compared. Results: Significant differences (p < 0.05) were found in the lymphocyte percentage, lymphocyte/monocyte ratio (LMR), hemoglobin and hematocrit concentration (lower in diabetic patients), monocyte percentage, and neutrophil/ lymphocyte ratio (NLR) (higher in diabetic patients). In the biochemical parameters, the only significant difference was found in the glutamic-oxaloacetic transaminase (GOT) value, which was higher in the diabetic patients compared with the non-diabetic patients (p < 0.005). Conclusions: Diabetes is an important factor linked to inflammation, anemia, lymphopenia and monocytosis in patients undergoing HD. The LMR was the most powerful marker of inflammation in this patient series. Larger-scale studies are required to verify this evidence.
Downloads
References
Francis ER, Kuo CC, Bernabe-Ortiz A, Nessel L, Gilman RH, Checkley W, et al. Burden of chronic kidney disease in resource-limited settings from Peru: a population-based study. BMC Nephrol. 2015; 16:114.
Arrunategui-Correa V. Despistaje de diabetes mellitus tipo 2 en una población adulta urbana del distrito de Coishco, Ancash, Peru. Rev Med Hered. 2015; 26:173-6.
Packham DK, Alves TP, Dwyer JP, Atkins R, De Zeeuw D, Cooper M, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012; 59:75–83.
Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 146-54. 5. Al-Sayyari AA, Shaheen FA. End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene. Saudi Med J. 2011; 32:339-46.
Meneses Liendo V, Rabanal Leon C, Huapaya Carrera J, Cieza Zevallos J. Sobrevida en hemodiálisis según el periodo de ingreso de pacientes entre 1982 y 2007 en Lima, Perú. Rev Med Hered. 2011; 22(4):157-61.
Herrera Añazco P, Hernandez AV, Mezones-Holguin E. Diabetes mellitus y nefropatía diabética en el Perú. Rev Nefrol Dial Transpl. 2015; 35(4):229-37.
Herrera- Añazco P, Pacheco-Mendoza J, Taype-Rondan A. La enfermedad renal crónica en el Perú. Una revisión narrativa de los artículos científicos publicados. Acta Med Peruana. 2016; 33(2): 130-7.
Ramos W, López T, Revilla L, More L, Huamaní M, Pozo M. Resultados de la vigilancia epidemiológica de diabetes mellitus en hospitales notificantes del Perú, 2012. Rev Peru Med Exp Salud Pública. 2014; 31(1):9-15.
Prakash J, Gupta T, Prakash S, Bhushan P, Usha, Sivasankar M, Singh. Non-diabetic renal disease in type 2 diabetes mellitus: Study of renal - retinal relationship. Indian J Nephrol. 2015; 25(4): 222–228.
Ejerblad E, Fored M, Lindblad P, Fryzek J, McLaughlim J, Nuyren D. Obesity and risk for chronic renal failure. J Amer Soc Nephrology 2006; 17(6):1695-1702.
España, Sociedad española de nefrología. Guías Terapéuticas Internacionales. 2006; 1-145.
Ahbap E, Sakaci T, Kara E, Sahutoglu T, Koc Y, Basturk T, et al. Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease. Clin Nephrol. 2016; 85(4):199-208.
Murat Akbas E, Demirtas L, Ozcicek A, Timuroglu A, Murat Bakirci E, Hamur H, et al. Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio with diabetic nephropathy. Int J Clin Exp Med. 2014; 7(7): 1794–1801
Villena J. Diabetes mellitus in Peru. Ann Glob Health. 2015; 81(6):765-75.
Kidney Disease - Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplement. 2013; 3(1):1-150.
Lepe-Zúñiga JL, Morales-Molina P, García-Nandayapa GA. Caracterización y correlación clínica de la linfopenia en la enfermedad renal en estadio terminal. Rev Med Inst Mex Seg Soc. 2016; 54(4):446-53.
Neto AA, Mansur A, Avakian SD, Gomes EP, Ramires JA. Monocitose é um marcador de risco independente para a doença arterial coronariana. Arq BrasCardiol. 2006; 86 (3): 1-5.
León-Pedroza JI, González-Tapia LA, del Olmo-Gil E, Castellanos-Rodríguez D, Escobedo G, González-Chávez A. Inflamación sistémica de grado bajo y su relación con el desarrollo de enfermedades metabólicas: de la evidencia molecular a la aplicación clínica. Cir Cir. 2015; 83( 6): 543-51.
Yaprak M, Turan MN, Dayanan R, Akın S, Değirmen E, Yıldırım M, et al. Platelet-to-lymphocyte ratio predicts mortality better than neutrophil-to-lymphocyte ratio in hemodialysis patients. Int Urol Nephrol. 2016; 48(8):1343-8.
Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ, The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Ren Fail. 2012; 34(2):155-9.
JJ, Zhang J, Zhang TY, Zhang S, Li BS. Prognostic value of peripheral blood lymphocyte-to-monocyte ratio in patients with solid tumors: a meta-analysis. Onco Targets Ther. 2016; 9: 37–47.
Draczevski L, Teixeira LM. Evaluation of the biochemical profile and hematological parameters in patients undergoing haemodialysis. Rev Saude Pes. 2011; 1: 15-22.
Harris E. Elevated liver function tests in type 2 diabetes. Clin Diabetes. 2005; 23(3):115-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
